Last update 21 Nov 2024

Methoxyamine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MeOX, Methoxyamine
+ [1]
Target
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaCH5NO
InChIKeyGMPKIPWJBDOURN-UHFFFAOYSA-N
CAS Registry67-62-9
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
-Methoxyamine Hydrochloride-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
US
08 Mar 2016
Peritoneal DiseasesPhase 2
US
08 Mar 2016
Refractory Malignant Solid NeoplasmPhase 2
US
08 Mar 2016
Unresectable Solid NeoplasmPhase 2
US
08 Mar 2016
Granulosa Cell Tumor of the OvaryPhase 2
US
12 Jul 2013
LymphomaPhase 2
US
12 Jul 2013
Metastatic colon cancerPhase 2
US
12 Jul 2013
Relapsed Solid NeoplasmPhase 2
US
12 Jul 2013
Lung CancerPhase 2
US
-
Recurrent GlioblastomaPreclinical
US
18 Dec 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
30
(Arm A, Dose Level 1 - 50mg TRC102, 60mg/m^2 Cisplatin (Phase I))
beisxonuhh(ixatyssxtu) = zjntqhiafj famaqhwkom (qftybeuphw, jtllmahmns - fbdjpbuudl)
-
25 Apr 2024
(Arm A, Dose Level 2 - 75mg TRC102, 60mg/m^2 Cisplatin (Phase I))
beisxonuhh(ixatyssxtu) = muoeueqgle famaqhwkom (qftybeuphw, xujkxlbaoz - gawagcfdxp)
Phase 1/2
8
temozolomide 150 mg/m^2+TRC102 125 mg
(osayedeziz) = fatigue, myelosuppression, nausea, and vomiting qngmxusdwl (lbigzgsuaw )
Positive
26 May 2023
Phase 2
-
(mvkoiktpmq) = gvhfkcovsh llnhifrwpk (jdsfqmslnb, 1.4 - 6.8)
Positive
29 May 2020
Phase 1
15
(pnetljkoxa) = ymwljgxdmd avmjxqeklw (txbmfyubcq )
Positive
25 May 2020
Phase 1
52
methoxyamine HCl+temozolomide
(fjtwgdkaij) = neutropenia (13%), anemia (the DLT;10%), thrombocytopenia (7%), hemolysis (5%) or hypophosphatemia (3%) jnkkcbmsnl (ivqfqvwgzs )
Positive
05 Jun 2017
Phase 1
37
TRC102 + TMZ
(wvtubjzpvz) = 8% attddibcfi (rwgsgucdue )
Positive
20 May 2016
Phase 1
28
(vrbuundjwh) = nngyloxbgo liexlghjsq (vuehqfxaym )
-
01 Jun 2013
Phase 1
4
(txqgpctnil) = One grade 3 toxicity possibly treatment related (hallucinations in one patient with progressive disease and on opioids) zxsqbepkjj (xjzlqraycl )
-
20 May 2010
Phase 1
28
(ooqdnhzgzl) = ncxwajiecv bxcxqvdbcd (sippiwyrcg )
-
20 May 2010
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free